Neuron23 key facts
as of Oct 2026- Developer of an artificial intelligence-based drug discovery model designed for genetically defined neurological and immunological diseases.
- Neuron23 is valued at approximately $271.5M as of Oct 2026 (last reported valuation).
- It has raised $310.0M; the latest was Later Stage VC ($96.5M) in Jun 2025.
- Notable investors include SoftBank Investment Advisers, Kleiner Perkins, Blue Owl Capital, Perceptive Advisors, Chimera Capital — 14 tracked in total.
- Status: Privately Held (backing).
Neuron23's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Neuron23: the Monday email on marks, rounds and moves
Neuron23 funding rounds
No funding rounds for Neuron23 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Neuron23
14+Neuron23 valuation
Neuron23's last reported valuation was $272 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
Neuron23 investors
14 investors are on record for Neuron23, including SoftBank Investment Advisers, Kleiner Perkins, Blue Owl Capital and Perceptive Advisors. By type, the record holds 3 hedge funds and 2 venture capital firms.
About Neuron23
Developer of an artificial intelligence-based drug discovery model designed for genetically defined neurological and immunological diseases. The company's platform leverages recent advances in human genetics, combined with its state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases, enabling patients suffering from genetic disorders with customized medicines.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2018
- Employees
- 54
- Website
- neuron23.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.